4-(三丁基锡烷基)-2-甲基噻唑 | 653564-10-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(三丁基锡烷基)-2-甲基噻唑
• 英文名称: 2-methyl-4-(tributylstannyl)thiazole
• CAS: 653564-10-4
• 化学式: C₁₆H₃₁NSSn
• 分子量: 388.205
• InChiKey: DKXMFMIIBQIUKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.51
• 重原子数：
  19
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-溴-5-三氟甲苯苯胺 、 4-(三丁基锡烷基)-2-甲基噻唑 在 三苯基膦 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ copper(l) iodide 、 potassium fluoride 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 7.0h， 以63%的产率得到2-(2-methyl-thiazol-4-yl)-5-trifluoromethyl-phenylamine
  参考文献：
  名称：

  WO2007/14922

  摘要：

  公开号：
• 作为产物：
  描述：

  三丁基氯化锡 在 正丁基锂 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 2.25h， 生成 4-(三丁基锡烷基)-2-甲基噻唑
  参考文献：
  名称：

  WO2007/14922

  摘要：

  公开号：

文献信息

• Design, synthesis and biological evaluation of bridged epothilone D analogues
  作者：Qiao-Hong Chen、Thota Ganesh、Peggy Brodie、Carla Slebodnick、Yi Jiang、Abhijit Banerjee、Susan Bane、James P. Snyder、David G. I. Kingston

  DOI：10.1039/b814823f

  日期：——

  Six epothilone D analogues with a bridge between the C4-methyl and the C12-methyl carbons were prepared in an attempt to constrain epothilone D to its proposed tubulin-binding conformation. Ring-closing metathesis (RCM) was employed as the key step to build the C4–C26 bridge. In antiproliferative assays in the human ovarian cancer (A2780) and prostate cancer (PC3) cell lines, and also in tubulin assembly assay, all these compounds proved to be less active than epothilone D.

  制备了六种表霉素D的类似物，这些类似物在C4-甲基和C12-甲基碳之间建立了桥接，旨在将表霉素D限制在其拟议的微管结合构象中。环关闭复分解反应（RCM）作为关键步骤，用于构建C4–C26桥。在人类卵巢癌（A2780）和前列腺癌（PC3）细胞系的抗增殖实验以及微管组装实验中，这些化合物的活性均低于表霉素D。
• [EN] NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES TÉTRAHYDROPYRIDOPYRIMIDINES POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018083081A1

  公开（公告）日：2018-05-11

  The present invention provides novel compounds having the general formula: wherein R1, R2 and R3 are as described herein, compositions including the compounds and methods of using the compounds.

  本发明提供具有一般式的新化合物：其中R1、R2和R3如本文所述，包括这些化合物的组合物和使用这些化合物的方法。
• Synthesis and biological evaluation of fluorescently labeled epothilone analogs for tubulin binding studies
  作者：Thota Ganesh、Jennifer K Schilling、Radha K Palakodety、Rudravajhala Ravindra、Natasha Shanker、Susan Bane、David G.I Kingston

  DOI：10.1016/j.tet.2003.10.024

  日期：2003.12

  The two fluorescently labeled epothilones 14 and 15 have been synthesized using a modification of Nicolaou's macrolactonization and Stille coupling strategy. The cytotoxicities of the compounds were 6.1 and 2.7 μg/mL, respectively, against the A2870 ovarian cancer cell line, and 0.5 and 1.0 μg/mL, respectively, against the PC-3 prostate cancer cell line. The critical concentration of tubulin was 0

  这两个荧光标记的埃坡霉素14和15是使用Nicolaou的大内酯化和Stille偶联策略的改进方法合成的。该化合物对A2870卵巢癌细胞系的细胞毒性分别为6.1和2.7μg/ mL，对PC-3前列腺癌细胞系的细胞毒性分别为0.5和1.0μg/ mL。在14和15的存在下，微管蛋白的临界浓度分别为0.5和1.0μM ，而紫杉醇的临界浓度为0.3μM。描述了溶液中与微管结合的两个分子的荧光特性。
• Macrocylic Inhibitors of Hepatitis C Virus
  申请人：Simmen Kenneth Alan

  公开号：US20090105302A1

  公开（公告）日：2009-04-23

  Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1 is —OR 6 , —NH—SO 2 R 7 ; R 2 is hydrogen, and where X is C or CH, R 2 may also be C 1-6 alkyl; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, or C 3-7 cycloalkyl; n is 3, 4, 5, or 6; R 4 and R 5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkoxy-carbonyl, amino, azido, mercapto, C 1-6 alkylthio, polyhaloC 1-6 alkyl, aryl or Het; W is aryl or Het; R 6 is hydrogen; aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; R 7 is aryl; Het; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1-4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1-3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

  HCV复制抑制剂的公式(I)及其N-氧化物、盐或立体异构体，其中每个虚线（由- - - - -表示）表示可选的双键；X为N、CH，其中X带有双键时为C；R1为—OR6、—NH—SO2R7；R2为氢，当X为C或CH时，R2也可以是C1-6烷基；R3为氢、C1-6烷基、C1-6烷氧基C1-6烷基或C3-7环烷基；n为3、4、5或6；R4和R5相互独立，为氢、卤素、羟基、硝基、氰基、羧基、C1-6烷基、C1-6烷氧基、C1-6烷氧基C1-6烷基、C1-6烷基羰基、C1-6烷氧羰基、氨基、偶氮基、巯基、C1-6烷基硫基、多卤素C1-6烷基、芳基或杂环基；W为芳基或杂环基；R6为氢、芳基、杂环基、C3-7环烷基，可选地被C1-6烷基取代；或C1-6烷基，可选地被C3-7环烷基、芳基或杂环基取代；R7为芳基、杂环基、C3-7环烷基，可选地被C1-6烷基取代；或C1-6烷基，可选地被C3-7环烷基、芳基或杂环基取代；芳基为苯基或萘基，每个可选地取代1-3个取代基；杂环基为含有1-4个杂原子的5或6元饱和、部分不饱和或完全不饱和的杂环，每个独立选择自N、O或S，并可选地取代1-3个取代基；包含化合物(I)的制药组合物和制备化合物(I)的方法。还提供了公式(I)的HCV抑制剂与利托那韦的生物利用度组合。
• Macrocyclic inhibitors of hepatitis C virus
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：US07666834B2

  公开（公告）日：2010-02-23

  Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR6, —NH—SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy-carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1-4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1-3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

  公式（I）及其N-氧化物、盐或立体异构体的HCV复制抑制剂，其中每个虚线（由- - - - -表示）表示可选的双键；X为N，CH，其中X带有双键时为C；R1为—OR6，—NH—SO2R7；R2为氢，且当X为C或CH时，R2也可以是C1-6烷基；R3为氢，C1-6烷基，C1-6烷氧基C1-6烷基或C3-7环烷基；n为3、4、5或6；R4和R5各自独立地为氢、卤素、羟基、硝基、氰基、羧基、C1-6烷基、C1-6烷氧基、C1-6烷氧基C1-6烷基、C1-6烷基羰基、C1-6烷氧基羰基、氨基、偶氮基、巯基、C1-6烷基硫代基、多卤C1-6烷基、芳基或Het；W为芳基或Het；R6为氢；芳基；Het；C3-7环烷基，可选择性地取代C1-6烷基；或C1-6烷基，可选择性地取代C3-7环烷基、芳基或Het；R7为芳基；Het；C3-7环烷基，可选择性地取代C1-6烷基；或C1-6烷基，可选择性地取代C3-7环烷基、芳基或Het；芳基为苯基或萘基，每个都可以选择性地取代1-3个取代基；Het是一个5或6成员饱和、部分不饱和或完全不饱和的杂环环，其中每个独立地从N、O或S中选择1-4个杂原子，并可选择性地取代1-3个取代基；含有化合物（I）的制药组合物和制备化合物（I）的过程也提供。还提供了公式（I）的HCV抑制剂与利托那韦的生物利用度组合。